RAGE activation induces invasiveness of RA fibroblast-like synoviocytes in vitro

Ligands for the receptor for advanced glycation endproducts (RAGE) are increased in RA synovial fluid (SF), serum and synovium. Since RAGE is present on fibroblast-like synoviocytes (FLS), the present study investigates whether the RAGE ligands HMGB-1 and AGEs are able to stimulate the characteristi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical and experimental rheumatology 2007-09, Vol.25 (5), p.740-742
Hauptverfasser: STEENVOORDEN, M. M. C, TOES, R. E. M, RONDAY, H. K, HUIZINGA, T. W. J, DEGROOT, J
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 742
container_issue 5
container_start_page 740
container_title Clinical and experimental rheumatology
container_volume 25
creator STEENVOORDEN, M. M. C
TOES, R. E. M
RONDAY, H. K
HUIZINGA, T. W. J
DEGROOT, J
description Ligands for the receptor for advanced glycation endproducts (RAGE) are increased in RA synovial fluid (SF), serum and synovium. Since RAGE is present on fibroblast-like synoviocytes (FLS), the present study investigates whether the RAGE ligands HMGB-1 and AGEs are able to stimulate the characteristic, pathological invasive behaviour of these cells. FLS were obtained during joint replacement surgery. FLS were seeded in serum free medium with HMGB-1 or glycated albumin (BSA-AGE) on transwell filters coated with Matrigel. The lower compartment contained medium with serum as a chemoattractant. After three days, the percentage of invading cells was determined and compared to the control invasion. Stimulation with HMGB-1 increased invasiveness to 125% compared to the control (p = 0.001). Addition of anti-RAGE antibody reduced this back to baseline (98%, p = 0.002). Stimulation with BSA-AGE, another RAGE ligand, increased invasiveness to 150% compared to the control (p = 0.003). Addition of anti RAGE was again able to reduce the increased invasiveness back to baseline (95%, p = 0.008). HMGB-1 and BSA-AGE stimulated the invasiveness of RA-FLS by activation of RAGE. As such, RAGE may be an interesting target for therapy directed at the inhibition of synoviocyte activation.
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_69058552</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>69058552</sourcerecordid><originalsourceid>FETCH-LOGICAL-p239t-4df0660e9aabc77521b55cb0ee7173d739ec3f3184759c02cdaa99549311329f3</originalsourceid><addsrcrecordid>eNpF0F1LwzAYBeAgipvTvyC90btCPpqkuRxjTkFQhsLuyts0gWjXzL5pYf_eohOvzs3DOXDOyJxJI3Jqyt05mVNheF5KtZuRK8QPSrmSSl-SGSupLhUXc_K6XW7WGdgURkghdlnomsE6nHIEDKPrHGIWfbZdZj7UfaxbwJS34dNleOziGKI9ph-fjSH18ZpceGjR3ZxyQd4f1m-rx_z5ZfO0Wj7nBy5MyovGU6WoMwC11VpyVktpa-qcZlo0WhhnhResLLQ0lnLbABgjCyMYE9x4sSD3v72HPn4NDlO1D2hd20Ln4oCVMlSWUvIJ3p7gUO9dUx36sIf-WP19MIG7EwC00PoeOhvw302zquBUfANwsGZP</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>69058552</pqid></control><display><type>article</type><title>RAGE activation induces invasiveness of RA fibroblast-like synoviocytes in vitro</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>STEENVOORDEN, M. M. C ; TOES, R. E. M ; RONDAY, H. K ; HUIZINGA, T. W. J ; DEGROOT, J</creator><creatorcontrib>STEENVOORDEN, M. M. C ; TOES, R. E. M ; RONDAY, H. K ; HUIZINGA, T. W. J ; DEGROOT, J</creatorcontrib><description>Ligands for the receptor for advanced glycation endproducts (RAGE) are increased in RA synovial fluid (SF), serum and synovium. Since RAGE is present on fibroblast-like synoviocytes (FLS), the present study investigates whether the RAGE ligands HMGB-1 and AGEs are able to stimulate the characteristic, pathological invasive behaviour of these cells. FLS were obtained during joint replacement surgery. FLS were seeded in serum free medium with HMGB-1 or glycated albumin (BSA-AGE) on transwell filters coated with Matrigel. The lower compartment contained medium with serum as a chemoattractant. After three days, the percentage of invading cells was determined and compared to the control invasion. Stimulation with HMGB-1 increased invasiveness to 125% compared to the control (p = 0.001). Addition of anti-RAGE antibody reduced this back to baseline (98%, p = 0.002). Stimulation with BSA-AGE, another RAGE ligand, increased invasiveness to 150% compared to the control (p = 0.003). Addition of anti RAGE was again able to reduce the increased invasiveness back to baseline (95%, p = 0.008). HMGB-1 and BSA-AGE stimulated the invasiveness of RA-FLS by activation of RAGE. As such, RAGE may be an interesting target for therapy directed at the inhibition of synoviocyte activation.</description><identifier>ISSN: 0392-856X</identifier><identifier>EISSN: 1593-098X</identifier><identifier>PMID: 18078623</identifier><language>eng</language><publisher>Pisa: Clinical and Experimental Rheumatology</publisher><subject>Antibodies, Anti-Idiotypic - pharmacology ; Arthritis, Rheumatoid - metabolism ; Arthritis, Rheumatoid - pathology ; Biological and medical sciences ; Cell Movement - drug effects ; Cell Movement - physiology ; Cells, Cultured ; Diseases of the osteoarticular system ; Glycation End Products, Advanced - pharmacology ; HMGB1 Protein - pharmacology ; Humans ; Inflammatory joint diseases ; Medical sciences ; Receptor for Advanced Glycation End Products ; Receptors, Immunologic - immunology ; Receptors, Immunologic - metabolism ; Synovial Membrane - drug effects ; Synovial Membrane - pathology</subject><ispartof>Clinical and experimental rheumatology, 2007-09, Vol.25 (5), p.740-742</ispartof><rights>2008 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=19956420$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18078623$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>STEENVOORDEN, M. M. C</creatorcontrib><creatorcontrib>TOES, R. E. M</creatorcontrib><creatorcontrib>RONDAY, H. K</creatorcontrib><creatorcontrib>HUIZINGA, T. W. J</creatorcontrib><creatorcontrib>DEGROOT, J</creatorcontrib><title>RAGE activation induces invasiveness of RA fibroblast-like synoviocytes in vitro</title><title>Clinical and experimental rheumatology</title><addtitle>Clin Exp Rheumatol</addtitle><description>Ligands for the receptor for advanced glycation endproducts (RAGE) are increased in RA synovial fluid (SF), serum and synovium. Since RAGE is present on fibroblast-like synoviocytes (FLS), the present study investigates whether the RAGE ligands HMGB-1 and AGEs are able to stimulate the characteristic, pathological invasive behaviour of these cells. FLS were obtained during joint replacement surgery. FLS were seeded in serum free medium with HMGB-1 or glycated albumin (BSA-AGE) on transwell filters coated with Matrigel. The lower compartment contained medium with serum as a chemoattractant. After three days, the percentage of invading cells was determined and compared to the control invasion. Stimulation with HMGB-1 increased invasiveness to 125% compared to the control (p = 0.001). Addition of anti-RAGE antibody reduced this back to baseline (98%, p = 0.002). Stimulation with BSA-AGE, another RAGE ligand, increased invasiveness to 150% compared to the control (p = 0.003). Addition of anti RAGE was again able to reduce the increased invasiveness back to baseline (95%, p = 0.008). HMGB-1 and BSA-AGE stimulated the invasiveness of RA-FLS by activation of RAGE. As such, RAGE may be an interesting target for therapy directed at the inhibition of synoviocyte activation.</description><subject>Antibodies, Anti-Idiotypic - pharmacology</subject><subject>Arthritis, Rheumatoid - metabolism</subject><subject>Arthritis, Rheumatoid - pathology</subject><subject>Biological and medical sciences</subject><subject>Cell Movement - drug effects</subject><subject>Cell Movement - physiology</subject><subject>Cells, Cultured</subject><subject>Diseases of the osteoarticular system</subject><subject>Glycation End Products, Advanced - pharmacology</subject><subject>HMGB1 Protein - pharmacology</subject><subject>Humans</subject><subject>Inflammatory joint diseases</subject><subject>Medical sciences</subject><subject>Receptor for Advanced Glycation End Products</subject><subject>Receptors, Immunologic - immunology</subject><subject>Receptors, Immunologic - metabolism</subject><subject>Synovial Membrane - drug effects</subject><subject>Synovial Membrane - pathology</subject><issn>0392-856X</issn><issn>1593-098X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpF0F1LwzAYBeAgipvTvyC90btCPpqkuRxjTkFQhsLuyts0gWjXzL5pYf_eohOvzs3DOXDOyJxJI3Jqyt05mVNheF5KtZuRK8QPSrmSSl-SGSupLhUXc_K6XW7WGdgURkghdlnomsE6nHIEDKPrHGIWfbZdZj7UfaxbwJS34dNleOziGKI9ph-fjSH18ZpceGjR3ZxyQd4f1m-rx_z5ZfO0Wj7nBy5MyovGU6WoMwC11VpyVktpa-qcZlo0WhhnhResLLQ0lnLbABgjCyMYE9x4sSD3v72HPn4NDlO1D2hd20Ln4oCVMlSWUvIJ3p7gUO9dUx36sIf-WP19MIG7EwC00PoeOhvw302zquBUfANwsGZP</recordid><startdate>20070901</startdate><enddate>20070901</enddate><creator>STEENVOORDEN, M. M. C</creator><creator>TOES, R. E. M</creator><creator>RONDAY, H. K</creator><creator>HUIZINGA, T. W. J</creator><creator>DEGROOT, J</creator><general>Clinical and Experimental Rheumatology</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>20070901</creationdate><title>RAGE activation induces invasiveness of RA fibroblast-like synoviocytes in vitro</title><author>STEENVOORDEN, M. M. C ; TOES, R. E. M ; RONDAY, H. K ; HUIZINGA, T. W. J ; DEGROOT, J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p239t-4df0660e9aabc77521b55cb0ee7173d739ec3f3184759c02cdaa99549311329f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Antibodies, Anti-Idiotypic - pharmacology</topic><topic>Arthritis, Rheumatoid - metabolism</topic><topic>Arthritis, Rheumatoid - pathology</topic><topic>Biological and medical sciences</topic><topic>Cell Movement - drug effects</topic><topic>Cell Movement - physiology</topic><topic>Cells, Cultured</topic><topic>Diseases of the osteoarticular system</topic><topic>Glycation End Products, Advanced - pharmacology</topic><topic>HMGB1 Protein - pharmacology</topic><topic>Humans</topic><topic>Inflammatory joint diseases</topic><topic>Medical sciences</topic><topic>Receptor for Advanced Glycation End Products</topic><topic>Receptors, Immunologic - immunology</topic><topic>Receptors, Immunologic - metabolism</topic><topic>Synovial Membrane - drug effects</topic><topic>Synovial Membrane - pathology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>STEENVOORDEN, M. M. C</creatorcontrib><creatorcontrib>TOES, R. E. M</creatorcontrib><creatorcontrib>RONDAY, H. K</creatorcontrib><creatorcontrib>HUIZINGA, T. W. J</creatorcontrib><creatorcontrib>DEGROOT, J</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical and experimental rheumatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>STEENVOORDEN, M. M. C</au><au>TOES, R. E. M</au><au>RONDAY, H. K</au><au>HUIZINGA, T. W. J</au><au>DEGROOT, J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>RAGE activation induces invasiveness of RA fibroblast-like synoviocytes in vitro</atitle><jtitle>Clinical and experimental rheumatology</jtitle><addtitle>Clin Exp Rheumatol</addtitle><date>2007-09-01</date><risdate>2007</risdate><volume>25</volume><issue>5</issue><spage>740</spage><epage>742</epage><pages>740-742</pages><issn>0392-856X</issn><eissn>1593-098X</eissn><abstract>Ligands for the receptor for advanced glycation endproducts (RAGE) are increased in RA synovial fluid (SF), serum and synovium. Since RAGE is present on fibroblast-like synoviocytes (FLS), the present study investigates whether the RAGE ligands HMGB-1 and AGEs are able to stimulate the characteristic, pathological invasive behaviour of these cells. FLS were obtained during joint replacement surgery. FLS were seeded in serum free medium with HMGB-1 or glycated albumin (BSA-AGE) on transwell filters coated with Matrigel. The lower compartment contained medium with serum as a chemoattractant. After three days, the percentage of invading cells was determined and compared to the control invasion. Stimulation with HMGB-1 increased invasiveness to 125% compared to the control (p = 0.001). Addition of anti-RAGE antibody reduced this back to baseline (98%, p = 0.002). Stimulation with BSA-AGE, another RAGE ligand, increased invasiveness to 150% compared to the control (p = 0.003). Addition of anti RAGE was again able to reduce the increased invasiveness back to baseline (95%, p = 0.008). HMGB-1 and BSA-AGE stimulated the invasiveness of RA-FLS by activation of RAGE. As such, RAGE may be an interesting target for therapy directed at the inhibition of synoviocyte activation.</abstract><cop>Pisa</cop><pub>Clinical and Experimental Rheumatology</pub><pmid>18078623</pmid><tpages>3</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0392-856X
ispartof Clinical and experimental rheumatology, 2007-09, Vol.25 (5), p.740-742
issn 0392-856X
1593-098X
language eng
recordid cdi_proquest_miscellaneous_69058552
source MEDLINE; Alma/SFX Local Collection
subjects Antibodies, Anti-Idiotypic - pharmacology
Arthritis, Rheumatoid - metabolism
Arthritis, Rheumatoid - pathology
Biological and medical sciences
Cell Movement - drug effects
Cell Movement - physiology
Cells, Cultured
Diseases of the osteoarticular system
Glycation End Products, Advanced - pharmacology
HMGB1 Protein - pharmacology
Humans
Inflammatory joint diseases
Medical sciences
Receptor for Advanced Glycation End Products
Receptors, Immunologic - immunology
Receptors, Immunologic - metabolism
Synovial Membrane - drug effects
Synovial Membrane - pathology
title RAGE activation induces invasiveness of RA fibroblast-like synoviocytes in vitro
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T06%3A53%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=RAGE%20activation%20induces%20invasiveness%20of%20RA%20fibroblast-like%20synoviocytes%20in%20vitro&rft.jtitle=Clinical%20and%20experimental%20rheumatology&rft.au=STEENVOORDEN,%20M.%20M.%20C&rft.date=2007-09-01&rft.volume=25&rft.issue=5&rft.spage=740&rft.epage=742&rft.pages=740-742&rft.issn=0392-856X&rft.eissn=1593-098X&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E69058552%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=69058552&rft_id=info:pmid/18078623&rfr_iscdi=true